## **COVID-19 vaccination schedule**

## Individuals not at greater risk of serious disease from COVID-19 infection

<b>Age</b> (years)	0-11	12-15	16-17	18-39	40+
Primary course + +	Vaccination not currently recommended	2 doses  Pfizer BioNTech (Comirnaty®)  >12 week interval <sup>4</sup>		2 doses  Pfizer (Comirnaty®) or  Moderna (Spikevax®)²  8 week interval	2 doses  Pfizer (Comirnaty®)  Moderna (Spikevax®)²  AstraZeneca (Vaxevria®)⁵  8 week interval
Booster +	$\otimes$	<b>⊗ No</b> Booster not recommended		✓ Yes  Pfizer BioNTech (Comirnaty®)  Moderna (Spikevax ®)² At least 3 month interval	
Infection	8	Wait at least 12 weeks between COVID-19 infection and COVID-19 vaccination <sup>4</sup>		Wait 4 weeks between COVID-19 infection and COVID-19 vaccination	

## Individuals who are at greater risk of serious disease from COVID-19 infection<sup>3</sup>

<b>Age</b> (years)	0-11	12-15	16-17	18-39	40+	
Primary course + +	Vaccination not currently recommended	2 doses¹ Pfizer BioNTech (Comirnaty®) 8 week interval		2 doses <sup>1</sup> Pfizer (Comirnaty®) or Moderna (Spikevax ®) <sup>2</sup> 8 week interval	2 doses¹ Pfizer (Comirnaty®) Moderna (Spikevax®)² AstraZeneca (Vaxevria®)⁵ 8 week interval	
Booster +	8	<b>⊗ No</b> Booster not recommended	✓ Yes  Pfizer BioNTech (Comirnaty®)  At least 3 month interval	<ul> <li>✓ Yes</li> <li>Pfizer BioNTech (Comirnaty®)</li> <li>or Moderna (Spikevax ®)²</li> <li>At least 3 month interval</li> </ul>		
Infection	8	Wait 4 weeks between COVID-19 infection and COVID-19 vaccination				

- <sup>1</sup>3rd dose is advised if the person was severely immunocompromised at the time of first or second dose (refer to Green Book for details)
- <sup>2</sup> The priming dose of Moderna Spikevax® COVID-19 Vaccine is 100 micrograms (0.5mL), The booster dose is 50 micrograms (0.25mL)
- <sup>3</sup> Health care, social care or care home staff, clinical risk groups, and those are severely immunosuppressed or their household contacts
- <sup>4</sup> This interval may be reduced to 8 weeks in periods of high incidence or where there was concern about vaccine effectiveness
- <sup>5</sup> Vaxevria should only be used in exceptional circumstances



This is provided as an illustrated guide and does not cover every scenario, replace the need for clinical assessment or supersede guidance within the Green Book.

Correct as at 01/12/2021 Version 0e

